Research programme: heart failure therapeutics - Cytokinetics/Amgen

Drug Profile

Research programme: heart failure therapeutics - Cytokinetics/Amgen

Alternative Names: Cardiac sacromere activators; CK 0689705; CK 1122534; CK 1213296; CK 1316719; CK 689705

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 03 Jan 2018 Preclinical development is ongoing in Heart failure (9230396; Cytokinetics Pipeline, January 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA
  • 01 Mar 2015 Cytokinetics and Amgen amend agreement to extend the term of joint research programme through December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top